The Technical AnalystExchange: NSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Aurobindo Pharma Limited Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.05% INR1 136.10
America/New_York / 8 mai 2024 @ 05:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 665 685 mill |
| EPS: | 47.23 |
| P/E: | 24.05 |
| Earnings Date: | May 25, 2024 |
| SharesOutstanding: | 585.94 mill |
| Avg Daily Volume: | 2.08 mill |
| RATING 2024-05-08 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 24.05 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 24.05 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
INR909.84 (-19.92%) INR-226.26 |
| Date: 2024-05-08 |
| Expected Trading Range (DAY) |
|---|
|
INR 1 102.31 - 1 169.89 ( +/- 2.97%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | INR1 136.10 (1.05% ) |
| Volume | 1.130 mill |
| Avg. Vol. | 2.08 mill |
| % of Avg. Vol | 54.40 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AUROPHARMA.NS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AUROPHARMA.NS
Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.